Efficacy of Lu-177-PSMA-617 Therapy in Metastatic Castration-resistant Prostate Cancer Patients, A Single-Center Experience

被引：0
|
作者：
Telli, T. [1 ]
Tuncel, M. [1 ]
Caglar, M. [1 ]
机构：
[1] Hacettepe Univ, Fac Med, Ankara, Turkey
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2020年 / 47卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OP-989
引用
收藏
页码：S492 / S492
页数：1
相关论文
共 50 条
  • [11] Comment on, 177Lu-PSMA-617 in metastatic, castration-resistant prostate cancer"
    Radtke, Jan Philipp
    Albers, Peter
    Giesel, Frederik Lars
    AKTUELLE UROLOGIE, 2022, 53 (02)
  • [12] 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients with a Single Functioning Kidney
    Zhang, Jingjing
    Kulkarni, Harshad R.
    Singh, Aviral
    Schuchardt, Christiane
    Niepsch, Karin
    Langbein, Thomas
    Baum, Richard P.
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60 (11) : 1579 - 1586
  • [13] 177Lu-PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer patients with a single functioning kidney
    Zhang, Jingjing
    Kulkarni, Harshad
    Singh, Aviral
    Schuchardt, Christiane
    Niepsch, Karin
    Langbein, Thomas
    Baum, Richard
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60
  • [14] Single Center Experience with a 4-Week 177Lu-PSMA-617 Treatment Interval in Patients with Metastatic Castration-Resistant Prostate Cancer
    Kemppainen, Jukka
    Kangasmaki, Aki
    Malaspina, Simona
    Pape, Bernd
    Jalomaki, Jarno
    Kairemo, Kalevi
    Kononen, Juha
    Joensuu, Timo
    CANCERS, 2022, 14 (24)
  • [15] 177Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer
    Sanli, Yasemin
    Simsek, Duygu Has
    Sanli, Oner
    Subramaniam, Rathan M.
    Kendi, Ayse Tuba
    BIOMEDICINES, 2021, 9 (04)
  • [16] 225Ac-PSMA-617/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience
    Fadi Khreish
    Niklas Ebert
    Martin Ries
    Stephan Maus
    Florian Rosar
    Hendrik Bohnenberger
    Tobias Stemler
    Matthias Saar
    Mark Bartholomä
    Samer Ezziddin
    European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47 : 721 - 728
  • [17] 225Ac-PSMA-617/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience
    Khreish, Fadi
    Ebert, Niklas
    Ries, Martin
    Maus, Stephan
    Rosar, Florian
    Bohnenberger, Hendrik
    Stemler, Tobias
    Saar, Matthias
    Bartholomae, Mark
    Ezziddin, Samer
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (03) : 721 - 728
  • [18] Response and tolerability after a single dose of Lu-177-PSMA-617 in patients with metastatic castration resistant prostate cancer: a multicenter Study
    Rahbar, Kambiz
    Schmidt, Matthias
    Heinzel, Alexander
    Eppard, Elisabeth
    Yordanova, Anna
    Claesener, Michael
    Bode, Axel
    Ahmadzadehfar, Hojjat
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57
  • [19] Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
    Daniel Groener
    Cam Tu Nguyen
    Justus Baumgarten
    Benjamin Bockisch
    Karen Davis
    Christian Happel
    Nicolai Mader
    Christina Nguyen Ngoc
    Jennifer Wichert
    Severine Banek
    Philipp Mandel
    Felix K. H. Chun
    Nikolaos Tselis
    Frank Grünwald
    Amir Sabet
    EJNMMI Research, 11
  • [20] Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
    Groener, Daniel
    Cam Tu Nguyen
    Baumgarten, Justus
    Bockisch, Benjamin
    Davis, Karen
    Happel, Christian
    Mader, Nicolai
    Ngoc, Christina Nguyen
    Wichert, Jennifer
    Banek, Severine
    Mandel, Philipp
    Chun, Felix K. H.
    Tselis, Nikolaos
    Gruenwald, Frank
    Sabet, Amir
    EJNMMI RESEARCH, 2021, 11 (01)
12345